Spectrum Pharmaceuticals (SPPI) Stock Price
Spectrum Pharmaceuticals Price
Revenue has compounded at 13.0% per year over the past 19 years to 10.11 M USD. Spectrum Pharmaceuticals's net margin stands at -772.2%, down from -109.8% several years earlier. The payout ratio is around 10% of earnings.
Spectrum Pharmaceuticals stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Spectrum Pharmaceuticals business model & stock analysis
Frequently asked questions about Spectrum Pharmaceuticals
The business model of Spectrum Pharmaceuticals Inc revolves around the development, acquisition, and commercialization of innovative drug therapies for various oncology and hematology indications. As a leading biopharmaceutical company, Spectrum focuses on creating targeted and efficient treatments to address unmet medical needs in areas such as solid tumors and blood-related cancers. By leveraging its expertise in drug discovery and development, Spectrum aims to provide patients with effective and personalized treatment options. With a commitment to enhancing patient outcomes, Spectrum Pharmaceuticals Inc remains dedicated to advancing the field of oncology through its diverse portfolio of therapeutic offerings.
Spectrum Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Spectrum Pharmaceuticals Inc in the market are companies such as Pfizer Inc, Johnson & Johnson, Novartis AG, Roche Holding AG, and Bristol-Myers Squibb Company.
Spectrum Pharmaceuticals Inc, a leading biopharmaceutical company, has a rich history and background. Founded in 1987, the company focuses on developing and commercializing innovative therapies for challenging diseases. With a primary focus on hematology and oncology, Spectrum specializes in developing medicines that target unmet medical needs. Over the years, they have successfully launched several important drugs, including FOLOTYN® and KHAPZORY®, which have played a crucial role in improving patient outcomes. Their commitment to research, development, and commercialization has positioned Spectrum Pharmaceuticals as a trusted name in the biopharmaceutical industry. With a strong track record and dedication to advancing patient care, Spectrum continues to make significant contributions in the healthcare sector.
Spectrum Pharmaceuticals Inc has achieved several significant milestones. The company received FDA approval for its flagship product, FUSILEV, in 2011, enhancing its position in the oncology market. Spectrum also launched ZEVALIN, a radioimmunotherapy agent for treating relapsed or refractory non-Hodgkin's lymphoma, in partnership with Bayer Healthcare. Furthermore, the company expanded its product portfolio through acquisitions, including the purchase of Talon Therapeutics and Allos Therapeutics. Spectrum's dedication to innovation and strategic partnerships has enabled it to solidify its presence in the pharmaceutical industry and deliver value to its stakeholders.
Spectrum Pharmaceuticals Inc primarily operates in the United States.
Spectrum Pharmaceuticals Inc represents values of excellence, innovation, and patient-centricity. With a strong corporate philosophy focused on developing targeted therapies for challenging diseases, Spectrum is dedicated to improving the lives of patients through cutting-edge research and development. The company's commitment to fostering a culture of integrity, collaboration, and respect sets them apart in the pharmaceutical industry. Spectrum Pharmaceuticals Inc strives to create value for patients, shareholders, and healthcare providers by delivering high-quality and differentiated therapeutic options. With a customer-driven approach, Spectrum aims to positively impact healthcare outcomes while staying at the forefront of medical advancements.
10 analysts currently rate the Spectrum Pharmaceuticals stock: 0 recommend buying, 7 holding and 3 selling.
The Spectrum Pharmaceuticals share (SPPI) is listed on 5 stock exchanges, including: NASDAQ (SPPI), SIX (Zürich) (NTR.SW), Frankfurt (NTR.F), München (NTR.MU), Düsseldorf (NTR.DU).
Spectrum Pharmaceuticals Inc is a US-based publicly traded company that specializes in the development and marketing of cancer medications. The company is headquartered in Irvine, California and has been active in the industry since 1996. The company's business model includes providing cancer medications in various stages of clinical development, from preclinical research to market launch. With this approach, Spectrum Pharmaceuticals aims to meet the demand for innovative and effective cancer therapies. Spectrum Pharmaceuticals' product range includes several medications in different stages of development. One of the key products, already approved and commercially available in the US, is Belinostat, a histone deacetylase inhibitor (HDAC inhibitor) used for the treatment of peripheral T-cell lymphoma (PTCL). PTCL is a rare, aggressive cancer for which there is currently no specific treatment. Another product currently in clinical development is ROLONTIS, a pegylated granulocyte colony-stimulating factor (pegfilgrastim). ROLONTIS is intended for the treatment of neutropenia, a complication in cancer patients commonly caused by chemotherapy. Spectrum Pharmaceuticals also has other projects in its pipeline, including several in preclinical development. The company's goal is to offer a comprehensive range of cancer medications for a variety of cancer types. Another important aspect of Spectrum Pharmaceuticals' business model is collaboration with other companies and research institutions. The company has formed strategic partnerships with several biotech and pharmaceutical companies to conduct joint research and development projects. Through these partnerships, Spectrum Pharmaceuticals can expand its portfolio and share its resources and expertise with other companies. The company also pursues a growth strategy through mergers and acquisitions. In 2020, Spectrum Pharmaceuticals completed the acquisition of Hikma Pharmaceuticals' generic portfolio for US customers. The acquisition included 22 approvals for generic medications as well as a development team. Overall, Spectrum Pharmaceuticals focuses on a broad range of therapeutics to meet the demand for cancer medications. By collaborating with other companies and acquiring companies and product portfolios, the company aims to further expand its market position. Overall, Spectrum Pharmaceuticals' business model is focused on the development and marketing of cancer medications to meet the demand for innovative and effective cancer therapies. The company relies on a broad range of therapeutics and works closely with other companies and research institutions to expand its portfolio.
The revenue cannot currently be calculated for Spectrum Pharmaceuticals.
The profit cannot currently be calculated for Spectrum Pharmaceuticals.
The P/E ratio cannot be calculated for Spectrum Pharmaceuticals at the moment.
The P/S cannot be calculated for Spectrum Pharmaceuticals currently.
The Eulerpool Quality Score for Spectrum Pharmaceuticals is 1/10.
The ISIN of Spectrum Pharmaceuticals is US84763A1088. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Spectrum Pharmaceuticals is 164623. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Spectrum Pharmaceuticals is SPPI. The ticker symbol is used to trade Spectrum Pharmaceuticals shares on the stock exchange.
Spectrum Pharmaceuticals stock
Spectrum Pharmaceuticals Peer Group
Spectrum Pharmaceuticals Ticker
Spectrum Pharmaceuticals FIGI
All fundamentals and in-depth analysis of Spectrum Pharmaceuticals
Our stock analysis for Spectrum Pharmaceuticals stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Spectrum Pharmaceuticals. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.